Simris Alg AB (publ) Market Cap ($17.43 Million)
Market Cap & Net Worth: Simris Alg AB (publ) (SIMRIS-B)
Simris Alg AB (publ) market cap. Simris Alg AB (publ) (ST:SIMRIS-B) has a market capitalization of $17.43 Million (Skr161.98 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25387 globally and #508 in its home market, demonstrating a 0.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Simris Alg AB (publ)'s stock price Skr0.12 by its total outstanding shares 1349793273 (1.35 Billion). Also see Simris Alg AB (publ) cash conversion from operations for how efficiently the company converts equity into cash flow.
Simris Alg AB (publ) Market Cap History (2016–2026)
Simris Alg AB (publ) market cap history from 2016 to 2026. Data shows change from $1.47 Billion to $17.43 Million (-33.20% CAGR). Check latest Simris Alg AB (publ) stock price today for real-time trading data and today's change.
Index Memberships
Simris Alg AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.32 Billion | 0.11% | #114 of 281 |
Weight: Simris Alg AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Simris Alg AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Simris Alg AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Simris Alg AB (publ) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.85x
Simris Alg AB (publ)'s market cap is 3.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.47 Billion | $726.23K | -$19.35 Million | 2025.00x | N/A |
| 2017 | $869.00 Million | $851.63K | -$22.98 Million | 1020.39x | N/A |
| 2018 | $477.31 Million | $761.81K | -$23.97 Million | 626.54x | N/A |
| 2019 | $313.21 Million | $1.74 Million | -$26.91 Million | 179.69x | N/A |
| 2020 | $143.52 Million | $2.17 Million | -$25.60 Million | 66.26x | N/A |
| 2021 | $107.49 Million | $6.14 Million | -$28.36 Million | 17.52x | N/A |
| 2022 | $36.53 Million | $4.08 Million | -$24.42 Million | 8.95x | N/A |
| 2023 | $32.68 Million | $4.35 Million | -$37.30 Million | 7.51x | N/A |
| 2024 | $11.07 Million | $2.89 Million | -$34.60 Million | 3.83x | N/A |
| 2025 | $6.22 Million | $1.61 Million | -$26.81 Million | 3.85x | N/A |
Competitor Companies of SIMRIS-B by Market Capitalization
Companies near Simris Alg AB (publ) in the global market cap rankings as of November 5, 2026. Also see how large is Simris Alg AB (publ)'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Simris Alg AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Simris Alg AB (publ) (2016–2026)
Market capitalization of Simris Alg AB (publ) from 2016 to today. Between 2016 and today, Simris Alg AB (publ)'s market cap moved from $1.47 Billion to $ 17.43 Million, with a yearly change of -33.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr17.43 Million | +180.37% |
| 2025 | Skr6.22 Million | -43.83% |
| 2024 | Skr11.07 Million | -66.13% |
| 2023 | Skr32.68 Million | -10.54% |
| 2022 | Skr36.53 Million | -66.01% |
| 2021 | Skr107.49 Million | -25.10% |
| 2020 | Skr143.52 Million | -54.18% |
| 2019 | Skr313.21 Million | -34.38% |
| 2018 | Skr477.31 Million | -45.07% |
| 2017 | Skr869.00 Million | -40.91% |
| 2016 | Skr1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Simris Alg AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.43 Million USD |
| MoneyControl | $17.43 Million USD |
| MarketWatch | $17.43 Million USD |
| marketcap.company | $17.43 Million USD |
| Reuters | $17.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more